Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential
Relmada Therapeutics, Inc. on 6ix
Earlier from Relmada Therapeutics
- Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC
- Relmada Therapeutics Announces Oral Poster Presentation on REL-1017 at 2021 American Society of Clinical Psychopharmacology Annual Meeting
- Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results
- Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021
- Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021
Later from Relmada Therapeutics
- Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results
- Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
- Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
- Relmada Therapeutics Announces Proposed Public Offering of Common Stock
- Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
Follow Relmada Therapeutics into a list and get an email when it puts out news.
Follow Relmada Therapeutics